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Abstract
Objective To compare the efficacy and safety of three
polyspecific antivenoms for bites by pit vipers.
Design Randomised double blind comparative trial of three
antivenoms.
Setting Shell, Pastaza, southeastern Ecuador.
Participants 210 patients with incoagulable blood were
recruited from 221 consecutive patients admitted with snake
bite between January 1997 and December 2001.
Intervention One of three antivenoms manufactured in Brazil,
Colombia, and Ecuador, chosen for their preclinical potency
against Ecuadorian venoms.
Main outcome measures Permanent restoration of blood
coagulability after 6 and 24 hours.
Results The snakes responsible for the bites were identified in
187 cases: 109 patients (58%) were bitten by Bothrops atrox, 68
(36%) by B bilineatus, and 10 (5%) by B taeniatus, B brazili, or
Lachesis muta. Eighty seven patients (41%) received Colombian
antivenom, 82 (39%) received Brazilian antivenom, but only 41
(20%) received Ecuadorian antivenom because the supply was
exhausted. Two patients died, and 10 developed local necrosis.
All antivenoms achieved the primary end point of permanently
restoring blood coagulability by 6 or 24 hours after the start of
treatment in > 40% of patients. Colombian antivenom,
however, was the most effective after initial doses of 20 ml (two
vials), < 70 ml, and any initial dose at both 6 and 24 hours. An
initial dose of 20 ml of Colombian antivenom permanently
restored blood coagulability in 64% (46/72) of patients after 6
hours (P = 0.054 compared with the other two antivenoms) and
an initial dose of < 70 ml was effective at 6 hours (65%,
P = 0.045) and 24 hours (99%, P = 0.06). Early anaphylactoid
reactions were common (53%, 73%, and 19%, respectively, for
Brazilian, Colombian, and Ecuadorian antivenoms, P < 0.0001)
but only three reactions were severe and none was fatal.
Conclusions All three antivenoms can be recommended for
the treatment of snakebites in this region, though the
reactogenicity of Brazilian and Colombian antivenoms is a
cause for concern.
Introduction
Each year in Ecuador, 1200-1400 cases of snake bite are
reported in 19 of the 21 provinces. Reports from Santo
Domingo de los Colorados, Guayaquil,1 and Shell2 confirm its
importance. In “El Oriente,” east of the Andes, the principal ven-
omous species are Bothrops atrox (common lancehead) and B
bilineatus smaragdinus (two striped forest pit viper, also known as
Bothriopsis bilineata smaragdina). B taeniatus (speckled forest pit
viper, also known as Bothriopsis taeniata), the less common Both-
rops and Bothrocophias species and Lachesis muta (bushmaster)
cause some bites.3 4 The indigenous Amerindian peoples and
people of mixed European ethnicity, whose occupations include
farming and logging, are all at risk of snake bite. The principal
clinical effects of envenoming by B atrox are life threatening
bleeding and blood coagulation disorders, shock, and renal fail-
ure. Necrosis and bacterial infection at the site of the bite may
cause permanent physical handicap. Envenoming by B bilineatus
is usually less severe. Other species such as B brazili and L muta,
although potentially as dangerous as B atrox, rarely bite people.4
In an earlier preclinical laboratory study, the neutralising
potency of five antivenoms (Brazilian, Ecuadorian, Mexican, and
two Colombian) was tested against the venoms of B atrox,B asper,
and B xanthogrammus.5 6 The Brazilian antivenom proved most
effective, followed by the Ecuadorian and two Colombian
antivenoms. The Mexican antivenom showed absolutely no neu-
tralising activity against Ecuadorian Bothrops venoms, consistent
with its poor clinical reputation in Ecuador.5 We selected the
three most effective antivenoms for a double blind randomised
comparative clinical trial in Ecuador.
The main lethal effect of the venoms of the crotaline
(rattlesnake-like) pit vipers responsible for envenoming is intrac-
ranial or gastrointestinal haemorrhage resulting from vascular
endothelial damage, platelet dysfunction, and consumption
coagulopathy. These dangerous antihaemostatic disorders and
their reversal by specific antivenoms are reflected by whole blood
coagulability, which is easily assessed at the bedside with a simple
but sensitive 20 minute whole blood clotting test.7 8 We therefore
used this test to measure the efficacy of the three antivenoms in
restoring whole blood coagulability and observed early reactions
to assess safety.
Methods
Participants
During the five year period January 1997-January 2002, patients
of any age who presented with a history of snake bite at any time
during the day or night to Hospital Vozandes del Oriente, Shell,
Pastaza, Ecuador, were considered for the study, unless they had
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received antivenom within the previous 6 hours. Patients were
included if the result of the blood clotting test showed that their
blood would not coagulate.7 8 Patients or their relatives gave
informed consent for admission, investigation, and treatment. All
patients were admitted to the hospital and kept under
observation for at least 48 hours. History, physical examination,
and other relevant details were recorded on standard proformas.
All members of the medical team were involved in the study,
providing 24 hour cover.
Antivenom treatment and randomisation
We randomised patients in blocks of six to treatment with one of
three antivenoms5 9: Suero Antiofidico (Instituto Nacional de
Higiene y Medicina Tropical “Leopoldo Izquieta Perez” Guayaq-
uil, Ecuador); Soro Antibotropico (Instituto Butantan, San Paulo,
Brazil); and Antiveneno Polivalente (Instituto Nacional de Salud,
Bogota, Colombia).
The expiry dates of all the antivenoms used was December
2000 but from January 2001 until the end of the study, the Bra- zilian and Colombian antivenoms remained clear solutions and
their in vivo neutralising potencies were undiminished.10 By this
time the Ecuadorian antivenom had already run out (see below).
We calculated that we would need to recruit 100 patients to
each arm to detect an increase from 50% to 73% in the propor-
tion of patients with clotting blood at 6 hours (80% power). After
the 140th patient, the supply of Ecuadorian antivenom ran out,
but strict randomisation was maintained to either Brazilian or
Colombian antivenom. Allocation was determined by a table of
random numbers. The antivenoms were packaged in numbered
envelopes. The nurse on duty was responsible for drawing up the
antivenoms, all indistinguishable colourless solutions, into an
unmarked syringe so that the medical staff treating and assessing
the patient and the patient were effectively blinded.
Most patients received an initial dose of 20 ml (two vials) of
antivenom by intravenous injection over 10 minutes. A minority,
considered on admission to be severely envenomed, were given
higher initial doses of up to 70 ml (seven vials). Six hours after
the start of antivenom treatment, we checked blood coagulability
using the 20 minute clotting test. If the blood was still not coagu-
lable, we administered a second dose of 20 ml of antivenom. Fur-
ther doses were given at every six hours until blood coagulability
was restored permanently.
General treatment
All medical staff responsible for administering antivenom were
familiar with the signs of early anaphylactoid reactions and
watched the patients carefully for such signs. These were treated
with subcutaneous adrenaline (epinephrine) and intravenous
diphenhydramine and hydrocortisone, as was the current
practice in Ecuador at the time of the study. Pain was treated with
oral paracetamol, intravenous pethidine, or tramadol. Patients
received fresh compatible HIV negative blood if their packed cell
volume fell below 20%, and routine tetanus prophylaxis was
given. Local necrosis was treated by immediate surgical debride-
ment, gentamicin, and chloramphenicol.
Snakes responsible for the bites
Dead snakes brought to the hospital were labelled and preserved
in 10% formalin or 70% ethanol. They were formally identified at
the Fundacion Herpetologica Gustavo Orcés in Quito.
Laboratory investigations
Venous blood was sampled on admission, at 6, 12, 18, and 24
hours later, and then daily until patients were discharged from
hospital. Blood coagulability was determined by the 20 minute
clotting test.We obtained background levels of absorbance in the
enzyme immunoassay from blood samples taken from 100 rela-
Two striped forest pit viper (Bothrops bilineatus smaragdinus, also known as
Bothriopsis bilineata smaragdina) from Napo Province, Ecuador, within the
catchment area of this study. As many as 36% of our patients had been
envenomed by this species
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Fig 1 Flow of patient through study
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tives or friends of patients who had not been bitten in the past
and were considered representative of the normal population
within the study area.11 We froze residual plasma/serum from the
blood clotting test for detection of specific venom antigen by
enzyme immunoassay using the technique described by Ariarat-
nam et al12 but with an additional step before the wells were
coated with antiserum. Four millilitres of each antiserum was
passed over a CN-Br activated Sepharose 4B affinity column
(Sigma, Poole, Dorset) to which was bound 5 mg of each venom
to retain as much venom specific antibody as possible. Enzyme
immunoassays were developed for five different venoms (B atrox,
B bilineatus smaragdinus, B taeniatus, B brazili, and L muta). This
assay had been validated in a separate study by testing admission
samples from 57 patients selected because all had brought in the
dead snake (personal communication). Therapeutic antivenom
concentrations were measured by enzyme immunoassay in 103
patients.11
Statistical analysis
We constructed a database using Microsoft Access and
compared the efficacy of antivenoms and reaction rates with 2×3
tables. The relation between the dose of antivenom required and
the initial serum concentration of venom antigen was
determined with the Kruskal-Wallis test.
Results
Randomisation and clinical features
We recruited 210 patients with incoagulable blood (fig 1). Eighty
seven patients (41.4%) received Colombian INS antivenom, 82
Table 1 Comparison of groups of patients bitten by snakes in Ecuador, at randomisation before treatment with antivenom*
Colombian (n=87) Brazilian (n=82) Ecuadorian (n=41)
Mean (SD) age (years) 28.3 (18.4) 27.3 (17.1) 23.3 (15.6)
Age range (years) 2-80 4-62 4-54
Male/female 39/48 42/40 25/16
Mean (SD) time between bite and antivenom (hours) 6.8 (9.1) 8.3 (14.6) 8.4 (10.7)
Range of time before antivenom (hours) 0.2-51 0.2-102 0.3-40
Site of bite:
Foot/leg 47 34 20
Hand/arm 32 40 18
Other 6 6 2
Snake species identified 74 76 37
Snake brought with patient:
B atrox 5 7 1
B bilineatus 7 4 1
B taeniatus 1 0 1
Unidentified 0 1 1
Snake identified by venom EIA:
B atrox 45 44 20
B bilineatus 25 27 16
B taeniatus 3 2 1
B brazili 0 1 0
Lachesis muta 1 2 0
EIA=enzyme immunoassay.
*Numbers do not always sum to total because of missing data.
Table 2 Clinical features of envenoming in 210 patients bitten by snakes. All had incoagulable blood before randomisation to antivenom therapy*
Colombian (n=87) Brazilian (n=82) Ecuadorian (n=41)
Local:
Pain 76 79 37
Swelling 70 75 33
Local lymphadenopathy 27 26 10
Bleeding from bite site 44 38 26
Erythema 44 28 15
Blistering 25 7 6
Ecchymosis 27 26 13
Systemic:
Nausea 38 33 16
Vomiting 23 15 6
Fever (>37.5°C) 22 19 8
Syncope 10 13 7
Gingival bleeding 44 35 13
Blood in sputum/saliva/vomit 37 34 9
Epistaxis 12 15 4
Gross haematuria 16 17 10
Bleeding skin/mucosa 7 9 4
Blood in stool (melaena) 7 9 4
*Numbers do not always sum to total because of missing data.
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(39%) received Brazilian antivenom, but only 41 (19.5%) received
Ecuadorian antivenom because the supply ran out after the
140th patient (table 1). The groups of patients receiving the three
different antivenoms were similar in all respects on admission to
hospital and before they received treatment (tables 1 and 2).
Table 2 shows the clinical features of recruited patients.
Snakes responsible for bites
Twenty nine patients (14%) brought in the snake responsible for
the bite: 13 (45%) were identified as B atrox, 12 (41%) as B bilinea-
tus smaragdinus, 2 (7%) as B taeniatus, and 2 (7%) remained uni-
dentified (table 1). Specimens of B atrox ranged from 20-90 cm
(mean 43 cm, SD 22 cm) and B bilineatus 15-50 cm (34 cm, SD 14
cm) and the two B taeniatus specimens measured 150 cm and
180 cm. With the help of herpetologists and the results of
enzyme immunoassay we identified the snake responsible for
envenoming in 187 (89%) cases: 109 (58%) were bitten by B atrox,
68 (36%) by B bilineatus, 6 (3%) by B taeniatus, 1 (1%) by B brazili,
and 3 (2%) by L muta. The distribution of bites by the different
species was similar among the three groups (table 1).
Venom antigen detection
We assessed the serum concentrations of venom antigen from
admission to discharge in 148 patients out of the 180 who
received an initial dose of 20 ml of antivenom (samples from 32
patients were lost during transport from Shell to Quito).
Concentrations on admission correlated significantly with the
total volume of antivenom required to restore blood coagulabil-
ity permanently (P < 0.0001). In the small group of patients who
required more than 60 ml of antivenom, median venom antigen
concentrations were about fourfold to fivefold higher than those
in patients who required only 20 ml of antivenom (fig 2). The
time to venom clearance was also longer in patients who
required higher doses of antivenom (fig 3).
Efficacy of antivenom treatment
Two patients died. A 4 year old boy treated with Brazilian
antivenom and a 38 year old woman treated with Colombian
antivenom died 11 hours and 3 days, respectively, after being
bitten by B atrox.Both developed acute pulmonary oedema from
which they could not be resuscitated. Ten patients (5% in each
treatment group) developed local necrosis. All other patients
were well on discharge from hospital.
Table 3 gives details of the comparative efficacy of the
antivenoms. One hundred and eighty patients were treated with
an initial dose of 20 ml (two vials). In those who received this
dose of Colombian antivenom, blood coagulability was restored
in 64% (46/72) at 6 hours compared with 49% (35/72) and 42%
(15/36) of those who received Brazilian and Ecuadorian
antivenoms, respectively (P = 0.054). Permanent restoration of
coagulability was recorded within 24 hours after starting
treatment in almost all patients given 20 ml of Colombian
antivenom (64/65; 99%), in 60/67 (90%) treated with the Brazil-
ian antivenom, and in 32/35 (91%) treated with the Ecuadorian
antivenom. Colombian antivenom also proved superior when
the initial dose was < 70 ml and after any initial dose of
antivenom (table 3). Eighty one patients (45%) required more
than one dose of antivenom, including 11 patients whose blood
became incoagulable again after a normal result from the whole
blood clotting test at 6 hours. There was no difference in median
total doses of the three antivenoms.
Therapeutic concentrations of antivenom
Of the 103 patients in whom we measured serum concentrations
of therapeutic antivenom, 63 had received an initial dose of 20
ml with or without subsequent doses. Antivenom was detectable
in the serum when serum venom antigenaemia had become
undetectable and for at least 48 hours, even in those who had
received only a single dose of antivenom (fig 4).
Antivenom reactions
Early reactions to antivenom were common, including rash,
vomiting, abdominal pain, fevers and chills, pruritis, and, more
seriously, dyspnoea and hypotension. In those receiving an initial
antivenom dose of 20 ml, reaction rates were 19% (7/37) in those
receiving Ecuadorian antivenom, 73% (56/71) for Colombian,
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Fig 2 Relation between median serum concentrations of venom antigen on
admission in patients requiring treatment with 20 ml (two vials), 40 ml (four
vials), 60 ml (six vials), and >60 ml of antivenom
Table 3 Permanent restoration of blood coagulability after various initial doses of antivenom at 6 and 24 hours after start of treatment
Initial dose
At 6 hours At 24 hours
No (%) of patients P value* No (%) of patients P value*
20 ml
Brazilian 35/72 (47) 0.054 60/67 (90) 0.10
Colombian 46/72 (64) 64/65 (99)
Ecuadorian 15/36 (42) 32/35 (91)
<70 ml
Brazilian 37/74 (50) 0.045 60/68 (88) 0.06
Colombian 48/74 (65) 66/67 (99)
Ecuadorian 15/36 (42) 32/35 (91)
Any initial dose
Brazilian 41/81 (51) 0.012 66/75 (88) 0.16
Colombian 59/87 (68) 77/80 (96)
Ecuadorian 17/40 (43) 36/39 (92)
*For comparison of Colombian antivenom with others.
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and 53% (37/70) for Brazilian antivenom. These rates were
significantly different from each other (P < 0.0001). Two patients
who developed hypotension had been treated with Colombian
antivenom, one with Brazilian antivenom, and one with Ecuado-
rian antivenom.
Discussion
In this randomised double blind comparative trial of three
polyspecific antivenoms in 210 patients with venom induced
coagulopathy, the resolution of coagulopathy at 6 and 24 hours
after the initial dose were the primary end points.We chose the 6
hour time interval because of the frequently reported
observation that, in envenomed patients, blood coagulability is
usually restored within 3-6 hours of the administration of a dose
of antivenom sufficient to neutralise circulating procoagulant
toxins.13–18 If an initial two vials (20 ml) of antivenom failed to
correct the coagulopathy within 6 hours, a further two vials were
given. Judged by this criterion, Colombian antivenom proved the
most effective.
We could not detect any difference in the ability of the three
antivenoms to eliminate or reduce local effects of envenoming.
Only 10 patients (5%) developed local necrosis, the main cause
of persistent morbidity in those who survive severe envenoming.
The pathophysiology of local envenoming may involve direct
and indirect inflammatory mechanisms that are independent of
neutralisation of venom toxins mediated through antivenom.19–22
The high incidence of symptoms of early anaphylactoid
reactions (including rash, vomiting, abdominal pains, fevers,
chills, pruritis, dypnoea, and hypotension) in our patients was
reminiscent of results of a study in Brazil in which reaction rates
as high as 84% were recorded.13 In other studies, early reaction
rates ranged from 3% to 54%.23–25 Among 178 patients who could
be closely monitored, 100 (56%) suffered early reactions. The
antivenoms differed significantly in their rates of reaction (Ecua-
dorian 19%, Brazilian 53%, Colombian 73%, P < 0.0001). The
higher reactogenicity of Colombian antivenom may reflect its
higher protein content (61 mg/ml) compared with the two other
antivenoms (Ecuadorian 47 mg/ml, Brazilian 44 mg/ml)5 and
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Fig 3 Clearance of venom antigen from 148 patients treated with one dose
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the fact that it is a whole IgG ammonium sulphate precipitated
preparation, whereas the other two antivenoms are pepsin
digested F(ab´)2 fragments.
5 Severe reactions were rare and were
promptly reversed by use of adrenaline, antihistamines, and
corticosteroids.
Enzyme immunoassay was useful for identifying the snake
responsible for envenoming. Concentrations of venom antigen
on admission correlated with the severity of envenoming, as in
studies of envenoming by Vipera aspis,26 B lanceolatus,27 and
Daboia siamensis.28 Patients whose venom antigenaemia was rela-
tively low required treatment with only two vials (20 ml) of
antivenom, whereas those with higher levels needed repeated
doses of antivenom. Venom clearance by antivenom occurred
more rapidly in patients with lower venom antigenaemias on
admission, as in patients bitten by B jararaca.29
B atrox and B bilineatus smaragdinus are responsible for most
snake bites in the Pastaza region. B atrox is notorious as the lead-
ing cause of severe snake bites wherever it occurs in South
America.4 16 In contrast, B bilineatus, a distinctive bright green
arboreal snake, is less well known as a snake of real medical
importance.30 In this study 36% of our patients were bitten by this
species and 6% by B taeniatus, B brazili, and L muta. Other crota-
lines including B pulcher (formerly B albocarinatus and also
known as Bothriopsis pulchra), Bothrocophias (formerly Bothrops
and Porthidium) hyoprora, and Bothrocophias microphthalmus are
known to inhabit this area of unusual diversity of venomous
snakes.4
Conclusions
All three of the tested antivenoms were clinically adequate in
eastern Ecuador. Colombian antivenom, however, was the most
effective judged by speed and efficiency in permanently correct-
ing venom induced coagulopathy. The Ecuadorian antivenom
was significantly less likely than either of the other two antiven-
oms to cause early anaphylactoid reactions. We recommended
that the Ecuadorian Ministry of Health should increase produc-
tion of this antivenom or, failing that, import either Colombian
or Brazilian antivenoms to improve the treatment of snake bite
envenoming in the Ecuadorian Amazon region.
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